SEC Comment Letter for TARO PHARMACEUTICAL INDUSTRIES LTD (CIK 0000906338) — May 7, 2020
TARO PHARMACEUTICAL INDUSTRIES LTD (CIK 0000906338)
Date: May 7, 2020 · CIK: 0000906338 · Accession: 0000000000-20-004002
AI Filing Summary & Sentiment
File numbers found in text: 001-35463
Letter
United States securities and exchange commission logo May 7, 2020 Daphne Huang Chief Financial Officer TARO PHARMACEUTICAL INDUSTRIES LTD 3 Skyline Drive Hawthorne, New York 10532 Re:TARO PHARMACEUTICAL INDUSTRIES LTD Form 20-F for Fiscal Year Ended March 31, 2019 Filed June 20, 2019 File No. 001-35463 Response Dated April 10, 2020 Dear Ms. Huang: We have reviewed your April 10, 2020 response to our comment letter and have the following comment. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Form 20-F for Fiscal Year Ended March 31, 2019 Note 2: - Significant Accounting Policies b. Financial statements in U.S. dollars, page F-12 1.Please confirm that you will expand your disclosures here and within MD&A, as appropriate, to disclose the nature and timing of the change, the actual and reasonably likely effects of the change, and economic facts and circumstances that led management to conclude that the change was appropriate. The effects of those underlying economic facts and circumstances on the registrant's business should also be discussed in MD&A. Refer to Section I-D of the Division of Corporation Finance's Frequently Requested Accounting and Financial Reporting Interpretations and Guidance, which is available on our website at http://www.sec.gov/divisions/corpfin/guidance/cfactfaq.htm.
FirstName LastNameDaphne Huang Comapany NameTARO PHARMACEUTICAL INDUSTRIES LTD May 7, 2020 Page 2 FirstName LastName Daphne Huang TARO PHARMACEUTICAL INDUSTRIES LTD May 7, 2020 Page 2 You may contact Tracey Houser at 202-551-3736 or Jeanne Baker at 202-551-3691, if you have questions regarding comments on the financial statements and related matters. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 7, 2020
Daphne Huang
Chief Financial Officer
TARO PHARMACEUTICAL INDUSTRIES LTD
3 Skyline Drive
Hawthorne, New York 10532
Re:TARO PHARMACEUTICAL INDUSTRIES LTD
Form 20-F for Fiscal Year Ended March 31, 2019
Filed June 20, 2019
File No. 001-35463
Response Dated April 10, 2020
Dear Ms. Huang:
We have reviewed your April 10, 2020 response to our comment letter and have the
following comment. Please respond to this comment within ten business days by providing the
requested information or advise us as soon as possible when you will respond. If you do not
believe our comment applies to your facts and circumstances, please tell us why in your
response. After reviewing your response to this comment, we may have additional comments.
Form 20-F for Fiscal Year Ended March 31, 2019
Note 2: - Significant Accounting Policies
b. Financial statements in U.S. dollars, page F-12
1.Please confirm that you will expand your disclosures here and within MD&A, as
appropriate, to disclose the nature and timing of the change, the actual and reasonably
likely effects of the change, and economic facts and circumstances that led management to
conclude that the change was appropriate. The effects of those underlying economic facts
and circumstances on the registrant's business should also be discussed in MD&A. Refer
to Section I-D of the Division of Corporation Finance's Frequently Requested Accounting
and Financial Reporting Interpretations and Guidance, which is available on our website
at http://www.sec.gov/divisions/corpfin/guidance/cfactfaq.htm.
FirstName LastNameDaphne Huang
Comapany NameTARO PHARMACEUTICAL INDUSTRIES LTD
May 7, 2020 Page 2
FirstName LastName
Daphne Huang
TARO PHARMACEUTICAL INDUSTRIES LTD
May 7, 2020
Page 2
You may contact Tracey Houser at 202-551-3736 or Jeanne Baker at 202-551-3691, if
you have questions regarding comments on the financial statements and related matters.
Sincerely,
Division of Corporation Finance
Office of Life Sciences